Novartis Launches Zero Profit Portfolio for Symptomatic Treatment of COVID-19

 Novartis Launches Zero Profit Portfolio for Symptomatic Treatment of COVID-19

Shots:

  • Novartis will offer a portfolio of 15 generic and OTC medicines addressing the need of low- and lower-middle-income countries to treat patients with COVID-19 symptoms. The medicines will available governments, NGOs, and other institutional customers in up to 79 countries at zero-profit to support financially strained healthcare systems
  • The Novartis’ COVID-19 portfolio aid to treat gastro-intestinal illness, acute respiratory symptoms, pneumonia, and septic shock. The portfolio will be offered in addition to the Novartis Access portfolio (on- and off-patent medicines against non-communicable diseases) via the local Novartis or Sandoz affiliate
  • The COVID-19 portfolio includes Amoxicillin, Ceftriaxone, Clarithromycin, Colchicine, Dexamethasone, Dobutamine, Fluconazole, Heparin, Levofloxacin, Loperamide, Pantoprazole, Prednisone, Prednisolone, Salbutamol, Vancomycin

Click here to read full press release/ article | Ref: Novartis | Image: Coroflot

Related News: Novartis Plans to Commence P-III Clinical Study Evaluating Canakinumab for Patients with COVID-19 Pneumonia

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post